Soligenix Stock Surges Above 200‑Day MA, Attracting Big‑Name Investors
Soligenix stock surges past its 200‑day moving average, sparking mixed analyst reviews and growing institutional interest in its rare‑disease biotech pipeline.
3 minutes to read
Soligenix Inc
Soligenix’s Phase 2a Wins: SG‑945 & SG‑302 Propel Small‑Cap Biotech Toward Orphan & Dermatology Breakthroughs
Soligenix’s Phase 2a wins for SG 945 in Behçet’s disease and SG 302 for psoriasis hint at orphan‑drug status and a new topical market, raising investor interest and potential upside.
4 minutes to read
Soligenix Inc. Stock Skyrockets Following Breakthrough Results in Behçet’s Disease Trial
Soligenix Inc.’s stock price surged 260% after the biotechnology company announced positive results from a clinical trial of its treatment for Behçet’s Disease, a chronic inflammatory disorder.
2 minutes to read
Soligenix Inc. Completes U.S. Manufacturing Shift, Eyes Growth in GPCR-Therapy Market
Soligenix Inc. has successfully transferred its synthetic hypericin manufacturing process to the US, positioning the biotech company for growth in the GPCR-targeting therapies market.
3 minutes to read